CY1124504T1 - Αντικαρκινικες συνθεσεις - Google Patents
Αντικαρκινικες συνθεσειςInfo
- Publication number
- CY1124504T1 CY1124504T1 CY20211100730T CY211100730T CY1124504T1 CY 1124504 T1 CY1124504 T1 CY 1124504T1 CY 20211100730 T CY20211100730 T CY 20211100730T CY 211100730 T CY211100730 T CY 211100730T CY 1124504 T1 CY1124504 T1 CY 1124504T1
- Authority
- CY
- Cyprus
- Prior art keywords
- arn
- prostate cancer
- hpmcas
- meth
- poly
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Η παρούσα εφεύρεση αφορά σε φαρμακευτικά σκευάσματα του ARN-509, τα οποία μπορεί να χορηγηθούν σε ένα θηλαστικό, συγκεκριμένα σε έναν άνθρωπο, που πάσχει από μια νόσο ή πάθηση που σχετίζεται με έναν υποδοχέα ανδρογόνων (androgen receptor, AR), συγκεκριμένα από καρκίνο, πιο συγκεκριμένα από καρκίνο του προστάτη, συμπεριλαμβανομένου χωρίς περιορισμό του ευνουχοάντοχου καρκίνου του προστάτη, του μεταστατικού ευνουχοάντοχου καρκίνου του προστάτη, του μεταστατικού ευνουχοάντοχου καρκίνου του προστάτη σε ασθενείς που είναι παρθένοι για χημειοθεραπεία, του καρκίνου του προστάτη που είναι ευαίσθητος σε βιοχημικώς υποτροπιάζουσες ορμόνες ή του μη μεταστατικού ευνουχοάντοχου καρκίνου του προστάτη υψηλού κινδύνου. Σε μία πτυχή, αυτά τα σκευάσματα συνίστανται σε μια στερεά διασπορά με ARN-509, ένα πολυ(μεθ)ακρυλικό συμπολυμερές και HPMCAS. Σε μία πτυχή, η στερεά διασπορά με ARN-509, ένα πολυ(μεθ)ακρυλικό συμπολυμερές και HPMCAS μπορεί να προκύψει, συγκεκριμένα προκύπτει, μέσω εξώθησης τήγματος ενός μείγματος που συνίσταται σε ARN-509, ένα πολυ(μεθ)ακρυλικό συμπολυμερές και HPMCAS και προαιρετικά ακολούθως μέσω λειοτρίβησης του εν λόγω μείγματος από εξώθηση τήγματος. Σε μία πτυχή, η στερεά διασπορά με ARN-509, ένα πολυ(μεθ)ακριλικό συμπολυμερές και HPMCAS μπορεί να προκύψει, συγκεκριμένα προκύπτει, μέσω ξήρανσης με ψεκασμό ενός μείγματος που συνίσταται σε ARN-509, ένα πολι(μεθ)ακρυλικό συμπολυμερές και HPMCAS σε έναν κατάλληλο διαλύτη.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14196605 | 2014-12-05 | ||
| PCT/US2015/063671 WO2016090105A1 (en) | 2014-12-05 | 2015-12-03 | Anticancer compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124504T1 true CY1124504T1 (el) | 2022-07-22 |
Family
ID=52006907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100730T CY1124504T1 (el) | 2014-12-05 | 2021-08-13 | Αντικαρκινικες συνθεσεις |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US10285948B2 (el) |
| EP (2) | EP3925598A1 (el) |
| JP (1) | JP6830892B2 (el) |
| KR (1) | KR102387089B1 (el) |
| CN (1) | CN106999432A (el) |
| AR (1) | AR102925A1 (el) |
| AU (1) | AU2015358497B2 (el) |
| CA (1) | CA2969675C (el) |
| CL (1) | CL2017001373A1 (el) |
| CO (1) | CO2017005574A2 (el) |
| CR (1) | CR20170218A (el) |
| CY (1) | CY1124504T1 (el) |
| DK (1) | DK3226843T3 (el) |
| EA (1) | EA201791251A1 (el) |
| ES (1) | ES2883187T3 (el) |
| HR (1) | HRP20211140T1 (el) |
| HU (1) | HUE054935T2 (el) |
| IL (1) | IL252325A0 (el) |
| LT (1) | LT3226843T (el) |
| MA (1) | MA41111B1 (el) |
| MD (1) | MD3226843T2 (el) |
| MX (1) | MX2017007206A (el) |
| MY (1) | MY192931A (el) |
| NI (1) | NI201700068A (el) |
| PH (1) | PH12017500979A1 (el) |
| PL (1) | PL3226843T3 (el) |
| PT (1) | PT3226843T (el) |
| RS (1) | RS62421B1 (el) |
| SG (1) | SG11201704386VA (el) |
| SI (1) | SI3226843T1 (el) |
| TW (1) | TWI709403B (el) |
| UA (1) | UA123538C2 (el) |
| WO (1) | WO2016090105A1 (el) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201912719TA (en) | 2012-09-26 | 2020-02-27 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| CN106999432A (zh) | 2014-12-05 | 2017-08-01 | 阿拉贡药品公司 | 抗癌组合物 |
| AU2018351714A1 (en) | 2017-10-16 | 2020-04-30 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
| WO2020144646A1 (en) | 2019-01-10 | 2020-07-16 | Aragon Pharmaceuticals, Inc. | Apalutamide dispersed in applesauce for treating prostate cancer |
| AU2020215177A1 (en) | 2019-01-30 | 2021-08-12 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer based on molecular subtypes |
| JP2022523094A (ja) | 2019-01-30 | 2022-04-21 | アラゴン ファーマシューティカルズ，インコーポレイテッド | 転移性去勢感受性前立腺癌の治療のための抗アンドロゲン剤 |
| WO2020239478A1 (en) | 2019-05-28 | 2020-12-03 | Pharma Mar, S.A. | Trabectedin for treating sarcomas based on genomic markers |
| JP2023500935A (ja) | 2019-11-04 | 2023-01-11 | アラゴン ファーマシューティカルズ，インコーポレイテッド | 重度の肝障害を有する対象における非転移性去勢抵抗性前立腺癌の治療のためのアンドロゲン受容体阻害剤 |
| WO2021245285A1 (en) | 2020-06-05 | 2021-12-09 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer based on molecular subtypes |
| TW202228794A (zh) | 2020-09-04 | 2022-08-01 | 美商艾瑞岡醫藥公司 | 用於治療前列腺癌之方法 |
| WO2022195407A1 (en) | 2021-03-19 | 2022-09-22 | Aragon Pharmaceuticals, Inc. | Methods for treating prostate cancer |
| WO2023152611A1 (en) | 2022-02-11 | 2023-08-17 | Aragon Pharmaceuticals, Inc. | Apalutamide and relugolix for the treatment of prostate cancer |
| WO2023209555A1 (en) | 2022-04-26 | 2023-11-02 | Aragon Pharmaceuticals, Inc. | Approved drug products and methods for treating prostate cancer |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2742331B2 (ja) | 1992-03-31 | 1998-04-22 | ブリテイツシユ・テクノロジー・グループ・リミテツド | 癌治療に有用な１７位置換ステロイド |
| EP0901786B1 (en) | 1997-08-11 | 2007-06-13 | Pfizer Products Inc. | Solid pharmaceutical dispersions with enhanced bioavailability |
| EP1258254A4 (en) | 2000-02-21 | 2004-02-04 | Takeda Chemical Industries Ltd | COMPOSITIONS FOR DELAYED DELIVERY OF PHYSIOLOGICALLY ACTIVE COMPOUNDS THAT ARE LOW WATER-SOLUBLE, METHOD FOR THE PRODUCTION AND USE THEREOF |
| CZ20032225A3 (cs) | 2001-02-27 | 2003-11-12 | Astrazeneca Ab | Farmaceutická formulace |
| WO2002080902A1 (en) | 2001-04-02 | 2002-10-17 | Astrazeneca Ab | Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono- m toluidide and pvp |
| ATE480226T1 (de) | 2001-06-22 | 2010-09-15 | Bend Res Inc | Pharmazeutische zusammensetzung enthaltend schwer lösliche und säureempfindliche arzneistoffe und neutralisierte anionische polymere |
| SE0103424D0 (sv) | 2001-10-15 | 2001-10-15 | Astrazeneca Ab | Pharmaceutical formulation |
| BR0307515A (pt) | 2002-02-01 | 2004-12-07 | Pfizer Prod Inc | Método para fabricar dispersões de drogas amorfas sólidas secas por aspersão homogêneas usando bicos de pressão |
| WO2003077827A1 (fr) | 2002-03-19 | 2003-09-25 | Nippon Shinyaku Co., Ltd. | Procede de production de medicament solide en dispersion |
| CA2549572A1 (en) | 2003-12-15 | 2005-06-23 | Council Of Scientific & Industrial Research | Taste masked pharmaceutical compositions comprising bitter drug and ph sensitive polymer |
| HUE027894T2 (en) | 2006-03-27 | 2016-11-28 | Univ California | An androgen receptor modulator for the treatment of prostate cancer and androgen receptor related diseases |
| AR078033A1 (es) * | 2009-04-03 | 2011-10-12 | Plexxikon Inc | Una dispersion solida, que contiene al compuesto {3-[5-(4-(cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico, composiciones y formulaciones que comprenden a dicha dispersion solida; metodos para fabricar dicha dispersion solida, formas 1 y 2 de |
| EP3124481B1 (en) | 2010-02-16 | 2018-03-28 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
| CN102525876B (zh) * | 2010-12-15 | 2014-03-12 | 西安力邦医药科技有限责任公司 | 阿司匹林固体分散体、其制备方法、药物组合物和用途 |
| EP3333153A1 (en) | 2011-06-15 | 2018-06-13 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Nuclear receptor modulators and their use for the treatment and prevention of cancer |
| US20150037407A1 (en) | 2012-03-21 | 2015-02-05 | Emphascience, Inc. | Method to improve the safety of handling of high potency drugs in solid dosage forms without changing their efficacy |
| WO2013152342A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Anti-cancer mtor inhibitor and anti-androgen combination |
| US9481663B2 (en) | 2012-06-07 | 2016-11-01 | Aragon Pharmaceuticals, Inc. | Crystalline forms of an androgen receptor modulator |
| US10668156B2 (en) | 2012-06-22 | 2020-06-02 | Basf Se | Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers |
| BR112015002055A2 (pt) | 2012-08-24 | 2017-07-04 | Dow Global Technologies Llc | acetato succinato de hidroxialquil metil celulose, composição, dispersão sólida, processo para produzir uma dispersão sólida, forma de dosagem e cápsula de envoltório |
| EP3725778B1 (en) | 2012-09-11 | 2021-08-18 | Medivation Prostate Therapeutics LLC | Formulations of enzalutamide |
| US9977033B2 (en) | 2012-09-11 | 2018-05-22 | The Board Of Regents Of The University Of Texas System | Methods for assessing cancer recurrence |
| SG10201912719TA (en) * | 2012-09-26 | 2020-02-27 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| NZ708272A (en) | 2013-01-22 | 2020-07-31 | Hoffmann La Roche | Pharmaceutical composition with improved bioavailability |
| EP2969227B1 (en) | 2013-03-15 | 2019-05-08 | Iceutica Inc. | Abiraterone acetate formulation |
| WO2014167428A2 (en) | 2013-04-10 | 2014-10-16 | Shilpa Medicare Limited | Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide |
| JP2016528252A (ja) | 2013-08-12 | 2016-09-15 | トーカイ ファーマシューティカルズ， インコーポレイテッド | アンドロゲン標的治療を使用する新生物障害の処置のためのバイオマーカー |
| WO2015116696A1 (en) * | 2014-01-28 | 2015-08-06 | Massachusetts Institute Of Technology | Combination therapies and methods of use thereof for treating cancer |
| US20160346207A1 (en) * | 2014-02-05 | 2016-12-01 | Lek Pharmaceuticals D.D. | Solid Pharmaceutical Compositions Of Androgen Receptor Antagonists |
| CA2931114A1 (en) | 2014-02-06 | 2015-08-13 | F. Hoffmann-La Roche Ag | Interleukin-2 fusion proteins and uses thereof |
| TWI803187B (zh) | 2014-08-08 | 2023-05-21 | 日商中外製藥股份有限公司 | 包含４環性化合物的非晶質體之固體分散體及製劑 |
| CN106999432A (zh) | 2014-12-05 | 2017-08-01 | 阿拉贡药品公司 | 抗癌组合物 |
| MA41107A (fr) | 2014-12-05 | 2017-10-10 | Aragon Pharmaceuticals Inc | Compositions anti-cancéreuses |
| SI3226842T1 (sl) | 2014-12-05 | 2021-04-30 | Aragon Pharmaceuticals, Inc. | Protirakavi sestavki |
| AR108489A1 (es) * | 2016-06-03 | 2018-08-29 | Aragon Pharmaceuticals Inc | Composiciones antineoplásicas |
-
2015
- 2015-12-03 CN CN201580066235.3A patent/CN106999432A/zh active Pending
- 2015-12-03 ES ES15820351T patent/ES2883187T3/es active Active
- 2015-12-03 DK DK15820351.3T patent/DK3226843T3/da active
- 2015-12-03 MX MX2017007206A patent/MX2017007206A/es unknown
- 2015-12-03 KR KR1020177018243A patent/KR102387089B1/ko active IP Right Grant
- 2015-12-03 MA MA41111A patent/MA41111B1/fr unknown
- 2015-12-03 AU AU2015358497A patent/AU2015358497B2/en active Active
- 2015-12-03 LT LTEP15820351.3T patent/LT3226843T/lt unknown
- 2015-12-03 JP JP2017529774A patent/JP6830892B2/ja active Active
- 2015-12-03 SG SG11201704386VA patent/SG11201704386VA/en unknown
- 2015-12-03 EP EP21175525.1A patent/EP3925598A1/en active Pending
- 2015-12-03 US US15/533,229 patent/US10285948B2/en active Active
- 2015-12-03 SI SI201531686T patent/SI3226843T1/sl unknown
- 2015-12-03 PL PL15820351T patent/PL3226843T3/pl unknown
- 2015-12-03 TW TW104140459A patent/TWI709403B/zh active
- 2015-12-03 WO PCT/US2015/063671 patent/WO2016090105A1/en active Application Filing
- 2015-12-03 MD MDE20170154T patent/MD3226843T2/ro unknown
- 2015-12-03 CA CA2969675A patent/CA2969675C/en active Active
- 2015-12-03 UA UAA201707015A patent/UA123538C2/uk unknown
- 2015-12-03 PT PT158203513T patent/PT3226843T/pt unknown
- 2015-12-03 RS RS20211035A patent/RS62421B1/sr unknown
- 2015-12-03 MY MYPI2017701986A patent/MY192931A/en unknown
- 2015-12-03 HU HUE15820351A patent/HUE054935T2/hu unknown
- 2015-12-03 EP EP15820351.3A patent/EP3226843B1/en active Active
- 2015-12-03 CR CR20170218A patent/CR20170218A/es unknown
- 2015-12-03 EA EA201791251A patent/EA201791251A1/ru unknown
- 2015-12-04 AR ARP150103981A patent/AR102925A1/es unknown
-
2017
- 2017-05-16 IL IL252325A patent/IL252325A0/en unknown
- 2017-05-26 PH PH12017500979A patent/PH12017500979A1/en unknown
- 2017-05-29 CL CL2017001373A patent/CL2017001373A1/es unknown
- 2017-06-02 NI NI201700068A patent/NI201700068A/es unknown
- 2017-06-05 CO CONC2017/0005574A patent/CO2017005574A2/es unknown
-
2019
- 2019-03-19 US US16/357,821 patent/US11224575B2/en active Active
-
2021
- 2021-03-15 US US17/201,811 patent/US11911511B2/en active Active
- 2021-07-19 HR HRP20211140TT patent/HRP20211140T1/hr unknown
- 2021-08-13 CY CY20211100730T patent/CY1124504T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124504T1 (el) | Αντικαρκινικες συνθεσεις | |
| CY1123856T1 (el) | Αντικαρκινικες συνθεσεις | |
| CO2017005572A2 (es) | Composiciones anticancerígenas | |
| CY1122651T1 (el) | Μεθοδοι και συνθεσεις για προσδιορισμο της αντιστασης εναντι θεραπειας υποδοχεα ανδρογονου | |
| CY1124157T1 (el) | Προσδετες δικυκλικου πεπτιδιου ειδικοι για μτ1-mmρ | |
| CY1121907T1 (el) | Συζευγματα antidll3-antiσωmatoς-pbd και χρησεις αυτων | |
| CY1124407T1 (el) | Ενωσεις αναστολεα αυτοταξινης | |
| CY1121517T1 (el) | Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib | |
| MX2017003246A (es) | Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer. | |
| PH12018501153A1 (en) | Novel anti-claudin antibodies and methods of use | |
| BR112016013048A2 (pt) | anticorpos anti-dpep3 e métodos de uso | |
| CL2018000565A1 (es) | Compuestos derivados de piridinona dicarboxamida, inhibidores de bromodominio; composicion farmaceutica; combinacion farmaceutica; utiles en el tratamiento de enfermedades autoinmunitarias, inflamatorias, virales y cancer, entre otras. | |
| GT201700231A (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa | |
| EA201892828A1 (ru) | Противораковые композиции | |
| EP3242688A4 (en) | Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers | |
| MX2018015363A (es) | Metodos y composiciones para el tratamiento de la enfermedad celiaca, de la sensibilidad al gluten no celiaca y de la enfermedad celiaca refractaria. | |
| BR112017022682A2 (pt) | construções de caliqueamicina e métodos de uso | |
| AR108690A1 (es) | Anticuerpos contra el miembro 21 de la superfamilia del receptor del factor de necrosis tumoral (anti-tnfrsf21) y métodos de uso de los mismos |